Effects of sotagliflozin added to insulin in patients with type 1 diabetes

New England Journal of Medicine

Volumn 377, Issue 24, 2017, Pages 2337-2348

  Garg, Satish K ^a   Henry, Robert R ^b   Banks, Phillip ^c   Buse, John B ^f   Davies, Melanie J ^g   Fulcher, Gregory R ^h   Pozzilli, Paolo ⁱ   Gesty Palmer, Diane ^c   Lapuerta, Pablo ^c   Simó, Rafael ^j,k   Danne, Thomas ^l   McGuire, Darren K ^d   Kushner, Jake A ^e   Peters, Anne ^m   Strumph, Paul ^c  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LEXICON PHARMACEUTICALS INC   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e TEXAS CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF LEICESTER   (United Kingdom)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k INSTITUTO DE SALUD CARLOS III   (Spain)

^l HANNOVER MEDICAL SCHOOL   (Germany)

^m UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN; PLACEBO; SOTAGLIFLOZIN; (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; GLYCOSIDE; SODIUM GLUCOSE COTRANSPORTER;

ACIDOSIS; ADULT; ADVERSE OUTCOME; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; GENITAL TRACT INFECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SUICIDE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ADOLESCENT; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; INTENTION TO TREAT ANALYSIS; LEAST SQUARE ANALYSIS; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLYCATED HEMOGLOBIN A; GLYCOSIDES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INTENTION TO TREAT ANALYSIS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORT PROTEINS; YOUNG ADULT;

EID: 85031780039     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1708337     Document Type: Article

References (39)

1. Diabetes atlas. 7th ed. Brussels: International Diabetes Federation, 2015.
2. Imperatore G, Boyle JP, Thompson TJ, et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth Diabetes Care 2012 35 2515-20.
3. Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015; 38: 971-8.
4. McKnight JA, Wild SH, Lamb MJ, et al. Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med 2015; 32: 1036-50.
5. Weinstock RS, Schutz-Fuhrmann I, Connor CG, et al. Type 1 diabetes in older adults: comparing treatments and chronic complications in the United States T1D Exchange and the German/Austrian DPV registries. Diabetes Res Clin Pract 2016; 122: 28-37.
6. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med 2013; 369: 362-72.
7. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32: 1335-43.
8. Realsen J, Goettle H, Chase HP. Morbidity and mortality of diabetic ketoacidosis with and without insulin pump care. Diabetes Technol Ther 2012; 14: 1149-54.
9. National diabetes statistics report. Atlanta: Centers for Disease Control and Prevention, 2017 (https://www.cdc .gov/diabetes/data/statistics/statistics-report .html).
10. Number of emergency department visits (in thousands) with hypoglycemia as first-listed diagnosis and diabetes as secondary diagnosis, adults aged 18 years or older, United States, 2006-2009. Atlanta: Centers for Disease Control and Prevention, 2014 (https://www.cdc .gov/diabetes/statistics/hypoglycemia/fig1 .htm).
11. Lapuerta P, Zambrowicz B, Strumph P, Sands A. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diab Vasc Dis Res 2015; 12: 101-10.
12. Zambrowicz B, Ogbaa I, Frazier K, et al. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects. Clin Ther 2013; 35: 1162-1173.e8.
13. Dobbins RL, Greenway FL, Chen L, et al. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. Am J Physiol Gastrointest Liver Physiol 2015; 308: G946-G954.
14. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015; 38: 1181-8.
15. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibi tor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012; 92: 158-69.
16. Bode BW, Garg SK. The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes. Endocr Pract 2016; 22: 220-30.
17. Einarson TR, Garg M, Kaur V, Hemels ME. Composite endpoints in trials of type-2 diabetes. Diabetes Obes Metab 2014; 16: 492-9.
18. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015; 17: 928-35.
19. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015; 38: 2258-65.
20. Mathieu C, Zinman B, Hemmingsson JU, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 2016; 39: 1702-10.
21. Petrie JR, Chaturvedi N, Ford I, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5: 597-609.
22. Garg SK, Moser EG, Bode BW, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract 2013; 19: 19-28.
23. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 2011; 28: 1176-81.
24. Lyons SK, Hermann JM, Miller KM, et al. Use of adjuvant pharmacotherapy in type 1 diabetes: international comparison of 49,367 individuals in the Diabetes Prospective Follow-up and T1D Exchange Registries. Diabetes Care 2017 August 2 (Epub ahead of print).
25. Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015; 100: 2849-52.
26. Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocr Pract 2016; 22: 753-62.
27. Benstetter M. SGLT2 inhibitors: PRAC makes recommendations to minimise risk of diabetic ketoacidosis. Healthcare professionals should be aware of possible atypical cases. London: European Medicines Agency, 2016.
28. Hine J, Paterson H, Abrol E, Russell-Jones D, Herring R. SGLT inhibition and euglycaemic diabetic ketoacidosis. Lancet Diabetes Endocrinol 2015; 3: 503-4.
29. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015; 38: 1680-6.
30. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38: 1687-93.
31. Hayami T, Kato Y, Kamiya H, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig 2015; 6: 587-90.
32. Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig 2016; 7: 135-8.
33. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care 2015; 38: 412-9.
34. Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017; 376: 2300-2.
35. American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment. Diabetes Care 2017; 40: Suppl 1: S64-S74.
36. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulin pump therapy: a metaanalysis. Diabetes Care 2003; 26: 1079-87.
37. Heller S, White D, Lee E, et al. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. Health Technol Assess 2017; 21(20): 1-278.
38. Garg SK, Weinzimer SA, Tamborlane WV, et al. Glucose outcomes with the inhome use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 2017; 19: 155-63.
39. Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 2016; 316: 1407-8.